Opinion

Video

A Growing Incidence of Renal Masses

Neal Shore, MD, FACS, and Brian M. Shuch, MD, introduce themselves and discuss the growing incidence of kidney cancer, the general prognosis, and early signs and symptoms.

Related Videos
Oliver Sartor, MD, is featured in this series.
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma
November 4th 2024

Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma

Hannah Clarke
“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
October 29th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

Hannah Clarke Gina Mauro
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
September 25th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

Hannah Clarke
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC
September 19th 2024

Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC

Hannah Clarke
According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”
© 2024 MJH Life Sciences

All rights reserved.